



Three-dimensional printing (3DP) has 
been recently acknowledged as an 
opportunity to make a significant 
technological leap over traditional 
pharmaceutical manufacturing processes 
and to promote a digital revolution within 
healthcare [1]. 
3DP technology, which comprises a variety 
of 3D-printing techniques, stands out for its 
applications [2-5]:
• Production of dosage forms on demand, 
with a specific and precise dose;
• Incorporation of multiple active 
pharmaceutical ingredients (APIs) into a 
single dosage form;
• Modulation of the drug release kinetics by 
tailoring the shape, size and structure of 
the printed dosage forms;
• Manufacture of complex dosage forms 
with API multidoses and tailored release 
profiles;
• Ability to manufacture a dosage form 
containing a liquid or semisolid embedded 
in a solid structure.
AIM
This work aims at evaluating the 
advantages and drawbacks of implementing 
3DP technologies in community pharmacies, 
towards patient centric manufacturing of 
medicines and as an add value to the 
current dispensing and counselling practice. Emergent 3DP can potentially contribute to better 
patient driven medicines since individualized 
medicines improve adhesion, safety and efficacy without 
sacrificing the quality of existing therapies. 
Although the application of the technology is at its early 
stages, one can anticipate a promising future with a fast 
implementation and use of this novel medicines, 
profiting from a favorable environment (e.g. industry 4.0, 
nanotechnology, patient and patients’ associations 
higher involvement in health care management).
Stakeholders in the pharmaceutical area are, through 
research, paving the way to readily available medicines, 
tailored according to the patient’s need, thus reinforcing 
the pharmacist role as a healthcare provider. 
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METHOD
The state of the art was reviewed in different 
perspectives, using a SWOT analysis 
(Strengths, Weakness, Opportunities and 
Threats) as an embodiment of the existing 
information and projecting 3DP into the long 
term future.
Strengths
• Design and development of individualized medicines 
with flexible and precise dosages for patients with 
chronic or rare diseases (e.g. orphan drugs);
• Design ab initio of medicines for specific patient 
groups (e.g. pediatric and geriatric populations) or 
patients with specific problems (e.g. kidney or hepatic 
impairment);
• Manufacturing of medicines closer to patients;
• Manufacturing advantages of medicines compared to 
traditional industrial manufacture (e.g. scale up not 
required, flexibility on dosing and drugs’ association);
• Eligibility for implementation in compounding 
pharmacies;
• Increased role of pharmacists in patient care;
• Overall promotion of pharmacists as service providers. 
Weaknesses
• Requirement of trained personnel and technical / 
technological qualified resources;
• Initial investment in equipment (e.g. printer) and 
software (e.g. licensing) by compounding pharmacies; 
• Running costs may increase;
• Daily professional practice must change;
• Specialization of compounding pharmacies.
Opportunities
• 3DP re-centers compounding pharmacy, increasing the 
value of this activity;
• Better interconnection between manufacturing and 
pharmaceutical advice;
• Improved relationship between pharmacists and 
patients throughout the manufacturing process;
• Higher involvement of patients and patients’ 
associations in the usage of medicines;
• Large benefits in compliance and health literacy.
Threats
• Co-participation and deep involvement of the 
medical and pharmaceutical classes in dealing with 
prescriptions for 3DP medicines;
• Physicians and pharmacists must change daily 
practice since medicines are designed, 
manufactured and prescribed for patients in a 
different way (prescribing practice must change due 
to complete freedom);
• Lack of expertise may compromise early initiatives;
• Stakeholders related to medicines may resist to 
changes (e.g. Health Authorities need to gain 
evidence on quality, safety and efficacy of printed 
medicines).
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